Inhibition of the BRAF oncoprotein by vemurafenib has been shown to be highly effective in BRAFV600E melanoma patients [22]; in contrast, the same treatment has limited effect on BRAFV600E colon cancer patients due to intrinsic resistance against BRAF inhibitors [6,23]. The gene discussed is BRAF; the disease is malignant colon neoplasm.